ERBB2 and breast cancer: While there was much attention to the ER+/HER2+ subgroup of breast cancer in the previous decade, less attention has been paid in the recent past, most probably because of the advent of trastuzumab treatment and many other antibody-based or kinase-based anti-HER2 treatments.